TDAC — Translational Development Acquisition Cashflow Statement
0.000.00%
Last trade - 00:00- $223.24m
- $222.80m
- 28
- 70
- 77
- 59
Annual cashflow statement for Translational Development Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | — | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -0.047 | -0.486 | -0.071 |
| Non-Cash Items | — | 0.482 | -0.121 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -0.05 | 0.003 | -0.66 |
| Change in Prepaid Expenses | |||
| Change in Accrued Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | -0.097 | -0 | -0.851 |
| Other Investing Cash Flow Items | — | — | -174 |
| Purchase of Investments | |||
| Cash from Investing Activities | — | — | -174 |
| Financing Cash Flow Items | -0.151 | 0 | 6.86 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 0.099 | 0 | 176 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0.002 | -0 | 0.436 |